Company profile: EG 427
1.1 - Company Overview
Company description
- Provider of pinpoint gene therapy using non-replicative HSV-1 vectors. Offers EG110A for neurogenic bladder dysfunction and overactive bladder; a platform delivering large genes with precise control and long-term expression for peripheral nervous system disorders; vector engineering with specific promoters for targeted sensory or autonomic neuronal subsets; and R&D expanding to chronic indications, including central nervous system neurons.
Products and services
- Pinpoint Gene Therapy Platform: Engineers an nrHSV-1-based gene delivery system that transports large genes with precise control and long-term expression to address peripheral nervous system disorders
- EG110A: Produces a non-replicative HSV-1-based vector in preclinical development for neurogenic bladder dysfunction and overactive bladder, enabling targeted gene delivery to peripheral neurons with long-term expression
- Vector Engineering Services: Custom-engineers nrHSV-1 vectors with specific promoters to achieve targeted effects in defined sensory or autonomic neuronal subsets of the peripheral nervous system
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EG 427
Santaris Pharma
HQ: Denmark
Website
- Description: Provider of RNA-targeted therapy discovery and development using proprietary LNA chemistry through its LNA Drug Platform and Drug Discovery Engine; a privately held, clinical-stage biopharmaceutical company focused on highly specialized, targeted drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santaris Pharma company profile →
DNA Therapeutics
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development as a privately held company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Therapeutics company profile →
Generation Bio
HQ: United States
Website
- Description: Provider of genetic medicines including iqDNA, a DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases; ctLNP, a cell-targeted lipid nanoparticle delivery system for specific tissue targeting enabling personalized, redosable treatments; and RES, a rapid enzymatic synthesis process that efficiently produces highly pure DNA constructs, aiming for global access to genetic medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generation Bio company profile →
Kriya Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kriya Therapeutics company profile →
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EG 427
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EG 427
2.2 - Growth funds investing in similar companies to EG 427
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EG 427
4.2 - Public trading comparable groups for EG 427
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →